Business
Cytek® Biosciences to Acquire Flow Cytometry and Imaging Business from DiaSorin
Sale of assets related to Flow Cytometry & Imaging (FCI) Business UnitAcquisition will expand Cytek’s product portfolio to include imaging and menu-based
About this update from Cytek Biosciences, Inc.
[{"type":"text","content":"Sale of assets related to Flow Cytometry & Imaging (FCI) Business UnitAcquisition will expand Cytek’s product portfolio to include imaging and menu-based application driven flow cytometry to provide full cell analysis solutions to its customersTransaction is in line with DiaSorin’s strategic priorities communicated to the market after Luminex acquisitionEmployees associated with commercial, operations, R&D and supporting functions expected to join Cytek SALUGGIA, Italy and FREMONT, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- DiaSorin (FTSE MIB: DIA) and Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced that Luminex Corporation, a wholly owned subsidiary of DiaSorin, has signed an agreement with Cytek to sell substantially all of its assets related to the Flow Cytometry & Imaging (FCI) business unit. The sale is expected to close within 30 days, subject to customary closing conditions. The FCI business unit, acquired by Luminex in October 2018, is based on both conventional flow cytometry and image-based flow cytometry instrumentation, which provide insights into all facets of cellular phenotypes and morphology. The FCI business unit includes dedicated commercial, operations, R&D, and supporting personnel. An existing installed base of more than 7,000 instruments will be under the Cytek umbrella following the acquisition, expanding the company’s global commercial footprint. The decision to sell the FCI business unit to Cytek is in line with the strategic priorities communicated to investors during the Capital Market Day in December 2021. “We are currently working on several projects that will allow DiaSorin to further growth and strengthen our positioning as a specialty player over the next years,” commented Angelo Rago, president of Luminex. “To do so, we need to be extremely focused on the core for our future and, therefore, we decided to sell the Flow Cytometry & Imaging business unit to a dedicated, leading player in the space. We are convinced that Cytek will be able to grow it with success in the future.” Over 60% of employees supporting the FCI business unit are within the commercial organization, including sales and marketing personnel, technical application scientists and field service engineers. These additions will greatly enhance Cytek’s ability to grow sales and service customers by expanding Cytek’s reach and its...